反义寡核苷酸NS-065/NCNP-01系统给药跳过53号外显子治疗杜氏肌营养不良
一项1期开放标签剂量递增试验评估了吗啉代反义寡核苷酸NS-065/NCNP-01在10例6至16岁杜氏肌营养不良患者中的安全性、药代动力学和活性。患者每周接受1.25、5或20 mg/kg剂量治疗12周,未观察到严重药物不良反应,7例患者肌营养不良蛋白/血影蛋白比值增加,外显子 skipping 呈剂量依赖性并与血浆Cmax和AUC0-t相关。
要点
- NS-065/NCNP-01在DMD患者中安全性良好,无严重药物不良反应。
- 外显子53跳跃呈剂量依赖性,7/10患者肌营养不良蛋白/血影蛋白比值增加。
- 外显子跳跃量与血浆Cmax和AUC0-t相关,支持进一步2期试验。
核心结论
- NS-065/NCNP-01具有良好的安全性特征和有前景的药代动力学,值得进一步开展2期临床试验。
研究设计与样本
- 1期、开放标签、剂量递增临床试验,纳入10例6至16岁携带可通过跳过53号外显子恢复阅读框突变的DMD患者。
- 患者每周接受NS-065/NCNP-01 1.25、5或20 mg/kg,持续12周,主要终点为安全性,次要终点为药代动力学和成功的外显子跳跃。
主要发现
- 未观察到严重药物不良反应,无治疗中断。
- NS-065/NCNP-01以剂量依赖性方式诱导肌营养不良蛋白mRNA中53号外显子跳跃。
- 10例患者中7例肌营养不良蛋白/血影蛋白比值增加。
- 外显子跳跃量与血浆最大药物浓度(Cmax)和血浆浓度-时间曲线下面积(AUC0-t)相关。
关键数值与推荐
- 给药剂量为1.25、5或20 mg/kg每周一次,持续12周。
- 10例患者中7例肌营养不良蛋白/血影蛋白比值增加。
- 外显子跳跃与血浆Cmax和AUC0-t相关。
临床怎么用
- 该1期结果支持在DMD患者中进一步开展2期临床试验评估NS-065/NCNP-01。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Duchenne muscular dystrophy (DMD) is a lethal hereditary muscle disease caused by mutations in the gene encoding the muscle protein dystrophin. These mutations result in a shift in the open reading frame leading to loss of the dystrophin protein. Antisense oligonucleotides (ASOs) that induce exon skipping correct this frame shift during pre-mRNA splicing and partially restore dystrophin expression in mouse and dog models. We conducted a phase 1, open-label, dose-escalation clinical trial to determine the safety, pharmacokinetics, and activity of NS-065/NCNP-01, a morpholino ASO that enables skipping of exon 53. Ten patients with DMD (6 to 16 years old), carrying mutations in the dystrophin gene whose reading frame would be restored by exon 53 skipping, were administered NS-065/NCNP-01 at doses of 1.25, 5, or 20 mg/kg weekly for 12 weeks. The primary endpoint was safety; the secondary endpoints were pharmacokinetics and successful exon skipping. No severe adverse drug reactions were observed, and no treatment discontinuation occurred. Muscle biopsy samples were taken before and after treatment and compared by reverse transcription polymerase chain reaction (RT-PCR), immunofluorescence, and Western blotting to assess the amount of exon 53 skipping and dystrophin expression. NS-065/NCNP-01 induced exon 53 skipping in dystrophin-encoding mRNA in a dose-dependent manner and increased the dystrophin/spectrin ratio in 7 of 10 patients. Furthermore, the amount of exon skipping correlated with the maximum drug concentration in plasma (Cmax) and the area under the concentration-time curve in plasma (AUC0-t ). These results indicate that NS-065/NCNP-01 has a favorable safety profile and promising pharmacokinetics warranting further study in a phase 2 clinical trial.
引用
- Komaki H, Nagata T, Saito T, et al. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Sci Transl Med. 2018. PMID: 29669851. doi:10.1126/scitranslmed.aan0713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。